Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary recombinant human prourokinase for slow flow/no-reflow during PCI in acute coronary syndrome
ChiCTR2500103336Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2025
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of recombinant human prourokinase in acute coronary syndrome (ACS) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Incidence of major cardiovascular events at 12 months after surgery. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2500103336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103336.